UK Liver Cancer Consultants

Mr Stephen Fenwick is a Consultant Hepatobiliary and General Surgeon based at the Sefton Suite Hospital and Aintree University Hospital in Liverpool.

Mr Fenwick qualified from Nottingham University and subsequently trained in Nottingham, Derby and Leeds, including a period of research for a Doctor of Medicine thesis, focusing on new treatments for patients with cancers which spread from the bowel to the liver.

Mr Fenwick was appointed as a Consultant Surgeon in 2008. He is also an Honorary Senior Lecturer at the University of Liverpool. He is currently the Clinical Lead of the Liverpool Hepatobiliary Unit, and also the Lead Cancer Clinician within the Hospital. A key development which Mr Fenwick has introduced has been the Advanced Colorectal Cancer Multidisciplinary Team Meeting, bringing together experts to ensure all patients with this condition have access to the best possible treatments.

The  Liverpool Hepatobiliary Unit is one of the busiest centres in Europe for the treatment of patients with benign and malignant conditions of the liver and biliary sytem. Each year Mr Fenwick  performs in excess of 100 major liver operations including laparoscopic (keyhole) liver resections, as well as around 150 laparoscopic cholecystectomies.

Mr Fenwick holds a number of external positions, including committee membership of specialist associtions, medical advisory board work for two patient charities, and as an independent Specialist Advisor for NICE.

Professor Ricky Sharma is a Professor of Clinical Oncology based at University College London.

Prof Sharma graduated in medicine from the University of Cambridge and then trained in general internal medicine, medical oncology and radiation oncology. He completed a PhD on DNA damage repair.  Since 2006, he has led a research group at the University of Oxford. 

He is the Laboratory Group Leader of the Translational DNA Repair Group at the CRUK/MRC Oxford Institute for Radiation Oncology at the University of Oxford. He is also a Higher Education Funding Council for England (HEFCE) Clinical Senior Lecturer at the University of Oxford, an Honorary Consultant in Clinical Oncology at the Oxford University Hospitals NHS Trust, and a Senior Research Fellow at Harris Manchester College, University of Oxford. His specialisms include radiotherapy, chemotherapy, bowel cancer, liver cancer, and liver-directed therapies.  

Dr Sharma has a prominent national and international profile in his field  and co-chairs the Early Phase Trials Workstream of the NCRI Clinical Translational Radiotherapy (CTRad) Group and is the Chief Investigator of the NCRN FOXFIRE, a multi-centre, clinical randomised clinical trial testing a new combination of chemotherapy and selective internal radiotherapy in the treatment of liver metastases from colorectal cancer.  He is an examiner for Royal College of Radiologists (Clinical Oncology) a member of Faculty Board and a prominent member of several working groups within the college, particularly on interventional oncology and undergraduate education.  He also tutors at Harris Manchester College and St Catherine's College, University of Oxford, Dr Sharma is a module leader for postgraduate teaching of radiobiology and oncology and is leading the development of a national mentorship scheme for clinical oncology trainees.  He was appointed as Chair of the Teaching Committee of the Oncology Department at the University of Oxford in May 2011.

Dr Sharma is a Fellow of both the Royal College of Physicians and the Royal College of Radiologists.

Professor Derek Manas is a Consultant Hepatobiliary and Transplant Surgeon based in Newcastle.

Prof Manas trained in Cape Town, South Africa and completed fellowships at Johns Hopkins - USA and Paul-Brousse, Paris. He was the recipient of the CJ Adams/Sandoz Traveling Fellowship to the UK in 1993 and joined the NHS in Newcastle in 1994. 

Professor Manas attained a personal chair in Transplantation at Newcastle University in 2007 and has been instrumental in successfully developing three super-region funded transplant programmes (Liver, Pancreas and Islet transplantation) in the North East of England, as well as establishing and managing Liver and Pancreas cancer surgery in Newcastle. 

Professor Manas is a member of NICE, Liver and Pancreas Advisory Groups, British Transplant Society, ELTA. He was recently involved in re-designing the organ donor retrieval service on a national level. 

Dr David Propper is a Consultant Medical Oncologist based at Barts and The London NHS Trust.

Dr Propper trained in medical oncology at the Imperial Cancer Research Fund Medical Oncology Unit in Oxford and received major trial research experience there. He subsequently spent time at the Lombardi Cancer Centre Georgetown Washington DC, USA.

Dr Propper has interests in translational research, early phase trials and the introduction of new therapeutic agents.

Dr Tony Dhillon is a Consultant Medical Oncologist based at The Royal Surrey County Hospital NHS Foundation Trust.

Dr Dhillon has been a consultant medical oncologist since 2010. He is a senior lecturer in Oncology at the University of Surrey and Imperial College London, looking into new treatment in GI cancers.

He treats colorectal, liver, pancreas, biliary, NET and GIST tumours.

Dr Dhillon trained in medical oncology at Imperial College Healthcare NHS Trust hospitals (Hammersmith and Charing Cross Hospitals) and Chelsea and Westminster and the Royal Free Hospital.

He has a PhD from Imperial College London in the field of cancer cell signaling funded by a CR-UK clinical training fellowship.

He has been a Wellcome Trust fellow at the University of Oxford and a lecturer in physiology at the University of Oxford.

Dr Sebastian Cummins is a Consultant Clinical Oncologist based at St. Luke's Cancer Centre at The Royal Surrey County Hospital in Guildford.

Dr Cummins specialises in upper and lower gastrointestinal malignancies and hepato-pancreatobiliary (liver and pancreas) malignancy.

He is based at St Lukes' Cancer Centre, from where he is involved in a wide range of research based protocols, both with regards to novel biological therapies and technical radiotherapy development.

Dr Paul Ross is a Consultant Medical Oncologist based at Guy’s & St Thomas’ NHS Foundation Trust, London, where he is Clinical Lead for Chemotherapy and he also consults from King’s College Hospital.  He was appointed Consultant in 2004.

Dr Ross graduated from Guy’s hospital, London after training at the Royal Marsden Hospital and complered a PhD at the institute for cancer research. 

He treats patients with colorectal cancer, oesophago-gastric cancer, pancreatic cancer, malignancies of the bile duct and gall bladder (cholangiocarcinoma) and primary liver cancer (hepatocellular cancer). In addition Dr Ross treats patients with neuroendocrine (carcinoid) tumours. He is focused on treating patients with cancer with chemotherapy and biological therapies. He has an interest in the use of locoregional therapies for liver tumours including SIRT.

Dr Ross is a member of the London Cancer New Drugs, which advises on the introduction of new drugs throughout the London area and their prioritisation.. He is Treasurer of the Association of Cancer Physicians of the United Kingdom. He is also a member of the advanced disease subgroup of the NCRI Colorectal Clinical Studies Group. 

He has been awarded the McElwain Prize, Association of Cancer Physicians in 2002 and previously in 2001 he was awarded the ASCO Merit Award, American Society of Clinical Oncology.

Dr Andrew Gaya is a Consultant Clinical Oncologist based at Guy's and St. Thomas' NHS Foundation Trust.

Dr Gaya originally qualified at St George’s Hospital Medical School (University of London) where he was awarded a distinction and several academic prizes. He trained in Clinical Oncology at Imperial College and St Bartholomew’s Hospital and subsequently undertook a Cancer Research UK MD Fellowship at University College London.

Dr Gaya treats solid tumours using chemotherapy, radiotherapy, and biological therapy – His main focus is on colorectal cancer, cancers of the oesophagus, stomach, pancreas, liver, and lung cancer. Dr Gaya’s main research interest is in the area of functional cancer imaging, where he is looking for ways to assess response to treatment much earlier and techniques for assessing blood flow and oxygen levels within cancers.

He is also heavily involved with the implementation of the latest radiotherapy techniques such as IMRT, IGRT and Tomotherapy, combining targeted or anti-vascular drugs with radiotherapy, and stereotactic body radiosurgery. He is one of the first UK doctors to use the CyberKnife stereotactic body radiosurgery unit. He has published widely in peer-reviewed journals, and is currently lead clinical oncologist for audit and clinical governance at Guy’s and St Thomas’ NHS Foundation Trust.

Mr Thomas Satyadas is a Consultant Hepatobiliary Surgeon based at The Central Manchester NHS Foundation Trust (Manchester Royal Infirmary).

Mr Satyadas is an advanced laparoscopic surgeon with extensive subspecialty training in liver and pancreas surgery (HPB). He is one of seven specialist liver and pancreas consultant surgeons at Manchester Royal Infirmary. The specialist training and prestigious overseas fellowships Mr Satyadas received in the UK (London and Cambridge), Europe (Paris, Heidelberg, Berlin) and Australia has provided him with extensive experience in performing complex General and Hepato-Pancreato-Biliary Surgical operations. 

After completing his Basic Surgical Training in London, Mr Satyadas undertook a period of surgical science research at the Royal Free University Hospital, London. His Higher Surgical Training was in the Cambridge Deanery. During this time he also obtained travelling fellowships to the world-renowned European Pancreatic Cancer Centre in Heidelberg and Liver Cancer Centre at the Virchow Klinikum in Berlin. 

Mr Satyadas completed his specialist training at the liver and pancreas surgery (Hepato-Pancreato-Biliary) in Cambridge. From there he pursued further specialist training by obtaining the fellowship at the Liver and Pancreatic Cancer Unit at the University of Adelaide for a period of 16 months. On completion, he worked in Paris for 6 months as a Laparoscopic liver and pancreas fellow. 

Professor Juan Valle is a Consultant Medical Oncologist based at The Christie NHS Foundation Trust in Manchester.

Prof Valle is an Honorary Professor in the Manchester Academic Health Sciences Centre (School of Cancer and Enabling Sciences). He is based in the department of Medical Oncology at The Christie within the gastrointestinal disease group and treats cancers of the pancreas, liver and biliary tract and neuroendocrine tumours. He is the Lead Clinician of The Christie’s Neuroendocrine Tumour service, awarded European Centre of Excellence status in March 2011.

Prof Valle is a member of the UK National Cancer Research Network (NCRN) upper gastrointestinal clinical studies group and a co-founding member of its cholangiocarcinoma working party. He also sits on the NCRN pancreatic cancer and hepatobiliary subgroups and chairs the Neuroendocrine subgroup. He has been awarded a number of grants for research leading to numerous publications and presentations, as well as national and international meetings, and he is a peer reviewer for a number of international medical journals. Prof Valle is a member of ASCO (American Society of Clinical Oncology), ESMO (European Society of Medical Oncology), UKI NETS (UK and Ireland Neuroendocrine Tumour Society) and ENETS (European Neuroendocrine Tumour Society).